Analysis for STE
$224.33
+7.07
(+3.25%)
- 📈 Growth — 22/30
- 💰 Profitability — 16/20
- 🏦 Financial Health — 16/20
- 💵 Valuation — 12/20
- ⚠️ Risk — 6/10
Overall Score: 70/100
Summary:
📈 Growth & Financial Trajectory
Over eight quarters, Revenues rose from about $1.33B to $1.49B, a roughly 12% increase. Net income progressed from around $178M to around $201M (peaking near $220M in 2026 Q4), indicating a positive trajectory with a minor dip in the latest quarter.
💰 Margins & Cash Flow
Gross margin stayed in the mid-40s percent range (44-46%), with operating margin near 19-21%. Cash flow from operations remained robust ($260M–$367M per quarter); investing cash flows were negative, and overall net cash flow turned positive in recent periods (e.g., $42.8M).
🛡️ Balance Sheet & Liquidity
Total assets around $10.1–$10.8B; equity about $6.4–$7.2B. Long-term debt around $1.7–$2.0B. Current assets comfortably exceed current liabilities, implying solid liquidity and modest leverage.
⚠️ Key Drivers & Risks
- Drivers: Healthcare capex strength and Sterilization/infection-prevention demand.
- Risks: Healthcare budget cyclicality and margin pressure; regulatory/acquisition integration risks.
📊 Key Financial Fundamentals
Valuation Multiples
Market Cap
$20.47B
P/E Ratio
25.42
Forward P/E
20.36
P/S Ratio
3.39
P/B Ratio
2.85
EV / EBITDA
13.43
Profitability & Returns
Gross Margin
44.37%
Operating Margin
18.85%
Net Margin
13.33%
ROE
11.28%
ROIC
8.90%
Financial Health & Liquidity
Current Ratio
1.91
Quick Ratio
1.17
Financial Scale & Cash Flow
Revenue
$6.04B
Net Income
$0.80B
FCF Yield
4.52%
Free Cash Flow
$0.93B
Total Debt To Equity
0.26